Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Sep;66(3):401-3.
doi: 10.1016/j.eururo.2013.12.055. Epub 2014 Jan 7.

A different method of evaluation of the ERSPC trial confirms that prostate-specific antigen testing has a significant impact on prostate cancer mortality

Marco Zappa  1 , Donella Puliti  2 , Jonas Hugosson  3 , Fritz H Schröder  4 , Pim J van Leeuwen  4 , Ries Kranse  5 , Anssi Auvinen  6 , Sigrid Carlsson  7 , Maciej Kwiatkowski  8 , Vera Nelen  9 , Alvaro Paez Borda  10 , Monique J Roobol  4 , Arnauld Villers  11
Affiliations

A different method of evaluation of the ERSPC trial confirms that prostate-specific antigen testing has a significant impact on prostate cancer mortality

Marco Zappa et al. Eur Urol. 2014 Sep.

Abstract

The advantages and disadvantages of two different methods of analyzing the European Randomized Study of Screening for Prostate Cancer (ERSPC) trial with respect to the effect of prostate-specific antigen (PSA) screening on prostate cancer (PCa) mortality (ie, disease-specific mortality analysis and excess mortality analysis) are discussed in depth. The traditional disease-specific mortality is the best end point, but it could be biased by misclassification of causes of death, and it does not take into account the possible effect of the screening process on other causes of death. Excess mortality analysis overcomes these problems, but the results could be biased if the expected mortality is not corrected for attendance status. Both methods, when applied to the ERSPC trials, demonstrate that no increase in non-PCa mortality occurred in the screening group and confirm that PSA screening decreases PCa mortality.

Keywords: Excess mortality; Screening.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The excess number of deaths
See this image and copyright information in PMC

Comment in

References

    1. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med. 2012 Mar 15;366(11):981–90. - PMC - PubMed
    1. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009 Mar 26;360(13):1320–8. - PubMed
    1. Lenner P. The excess mortality rate. A useful concept in cancer epidemiology Acta Oncol. 1990;29:573–6. - PubMed
    1. Otto SJ, Schröder FH, de Koning HJ. Low all-cause mortality in the volunteer-based Rotterdam section of the European randomised study of screening for prostate cancer: self-selection bias? J Med Screen. 2004;11(2):89–92. - PubMed
    1. Bergdahl AG, Aus G, Lilja H, Hugosson J. Risk of dying from prostate cancer in men randomized to screening: differences between attendees and nonattendees. Cancer. 2009;115(24):5672–9. - PubMed

Substances